[1]魏丽珍,陈玉珊,王艺敏.常规磁共振联合多模态磁共振成像对脱髓鞘假瘤与胶质瘤的鉴别诊断[J].福建医药杂志,2024,46(07):8-12.[doi:10.20148/j.fmj.2024.07.003]
　WEI Lizhen,CHEN Yushan,WANG Yimin.Conventional magnetic resonance combined with multimodal magnetic resonance imaging for differential diagnosis of demyelinating pseudotumor and glioma[J].FUJIAN MEDICAL JOURNAL,2024,46(07):8-12.[doi:10.20148/j.fmj.2024.07.003]
点击复制

常规磁共振联合多模态磁共振成像对脱髓鞘假瘤与胶质瘤的鉴别诊断()
分享到：

《福建医药杂志》[ISSN:1002-2600/CN:35-1071/R]

卷:
46
期数:
2024年07期
页码:
8-12
栏目:
临床研究
出版日期:
2024-11-20

文章信息/Info

Title:
Conventional magnetic resonance combined with multimodal magnetic resonance imaging for differential diagnosis of demyelinating pseudotumor and glioma
文章编号:
1002-2600(2024)07-0008-05
作者:
魏丽珍; 陈玉珊; 王艺敏
福建医科大学附属漳州市医院,漳州 363000
Author(s):
WEI Lizhen;  CHEN Yushan;  WANG Yimin
Zhangzhou Affiliated Hospital of Fujian Medical University, Zhangzhou, Fujian 363000, China
关键词:
脱髓鞘假瘤;  胶质瘤;  磁共振成像
Keywords:
demyelinating pseudotumor;  glioma;  magnetic resonance imaging
分类号:
R445.2
DOI:
10.20148/j.fmj.2024.07.003
文献标志码:
B
摘要:
目的 探讨常规磁共振与多模态磁共振对脱髓鞘假瘤诊断的价值,并分析脱髓鞘假瘤与胶质瘤的鉴别诊断要点。方法 回顾性分析我院收治的脱髓鞘假瘤患者61例与胶质瘤患者66例的临床资料、常规磁共振图像、多模态磁共振图像,评估各影像征象及影像参数对于疾病诊断的价值。结果 脱髓鞘假瘤好发于年轻女性患者,临床病程一般较缓慢,容易出现共济失调、运动障碍等症状,较少出现癫痫; 影像上脱髓鞘假瘤占位效应一般较轻,容易出现开环强化、中心静脉征、侧脑室垂直征等征象; 弥散加权成像(DWI)上病灶一般表现为不受限/弥散受限或者开环状弥散受限; 磁共振波谱成像(MRS)上脱髓鞘假瘤Cho/NAA、Cho/Cr值通常不高,NAA/Cr比值大于胶质瘤。胶质瘤MRI图像显示累及脑皮质的比率(80.3%)大于脱髓鞘假瘤累及脑皮质的比率(31.1%); 胶质瘤DWI显示大多为闭环强化; 57.6%的胶质瘤会出现中心结节状的弥散受限; MRS显示7例脱髓鞘假瘤表现为低灌注,仅有1例表现为高灌注,胶质瘤则全部表现为高灌注。结论 常规磁共振与多模态磁共振对脱髓鞘假瘤与胶质瘤的鉴别诊断有一定的价值。
Abstract:
Objective To explore the value of conventional magnetic resonance imaging(MRI)and multimodal MRI in the diagnosis of demyelinating pseudotumor, and to analyze the key points of differential diagnosis between demyelinating pseudotumor and glioma. Methods The clinical data, conventional MRI and multimodal MRI of 61 patients with demyelinating pseudotumor and 66 patients with glioma admitted to our hospital were analyzed retrospectively, and the value of imaging signs and imaging parameters for disease diagnosis was evaluated. Results Demyelinating pseudotumors were more common in young women, and the clinical course was generally slow, with more symptoms such as ataxia and dyskinesia and less epilepsy. On the image, the occupying effect of demyelinating pseudotumor was generally light, and it was easy to show signs such as open ring enhancement, central venous sign and lateral ventricular vertical sign. Lesions on diffusion-weighted imaging(DWI)generally appeared unrestricted/diffuse restriction or open-loop diffuse restriction; The Cho/NAA and Cho/Cr values of demyelinating pseudotumors on magnetic resonance spectroscopy(MRS)were usually not high, and the NAA/Cr ratio was greater than that of gliomas. MRI images of gliomas showed that the proportion of cerebral cortex involvement(80.3%)were greater than that of demyelinating pseudotumor(31.1%). Glioma DWI was often characterized by closed-loop enhancement; 57.6% of gliomas had central nodular diffusion restriction; MRS showed that seven cases of demyelinating pseudotumors showed hypoperfusion, only one case showed hyperperfusion, and all gliomas showed hyperperfusion. Conclusion Conventional MRI and multimodal MRI have certain value in the differential diagnosis of demyelinating pseudotumor and glioma.

参考文献/References:

[1] PATRIARCA L, TORLONE S, FERRARI F, et al. Is size an essential criterion to define tumefactive plaque? MR features and clinical correlation in multiple sclerosis[J]. The Neuroradiology Journal,2016, 29(5): 384-389.
[2] KATSUSE K, KURIHARA M, SUGIYAMA Y, et al. Apha-sic status epilepticus preceding tumefactive left hemisphere lesion in anti-MOG antibody associated disease[J]. Multiple Sclerosis and Related Disorders,2019, 27: 91-94.
[3] WEINSHENKER B G. Tumefactive demyelinating lesions: characteristics of individual lesions, individual patients, or a unique disease entity?[J]. Multiple Sclerosis(Houndmills, Basingstoke, England),2015, 21(13): 1746-1747.
[4] 戚晓昆,刘建国. 中枢神经系统瘤样脱髓鞘病变诊治指南[J]. 中国神经免疫学和神经病学杂志,2017, 24(5): 305-317.
[5] LIN X, YU W Y, LIAUW L, et al. Clinicoradiologic features distinguish tumefactive multiple sclerosis from CNS neoplasms[J]. Neurology Clinical Practice,2017, 7(1): 53-64.
[6] FRENCH H, FONTES-VILLALBA A, MAHARAJ M, et al. Tumefactive multiple sclerosis versus high grade glioma: a diagnostic dilemma[J]. Surgical Neurology International,2022, 13: 146.
[7] JEONG I H, KIM S H, HYUN J W, et al. Tumefactive demyelinating lesions as a first clinical event: Clinical, imaging, and follow-up observations[J]. Journal of the Neurological Sciences,2015(358): 118-124.
[8] YIU E M, LAUGHLIN S, VERHEY L H, et al. Clinical and magnetic resonance imaging(MRI)distinctions between tumefactive demyelination and brain tumors in children[J]. Journal of Child Neurology,2014, 29(5): 654-665.
[9] KOBAYASHI M, SHIMIZU Y, SHIBATA N, et al. Gadolinium enhancement patterns of tumefactive demyelinating lesions: correlations with brain biopsy findings and pathophysiology[J]. Journal of Neurology,2014, 261(10): 1902-1910.
[10] CORTESE R, MAGNOLLAY L, TUR C, et al. Value of the central vein sign at 3T to differentiate MS from seropositive NMOSD[J]. Neurology,2018, 90(14):1183-1190.
[11] SHARMA R, FISCHER M T, BAUER J, et al. Inflammation induced by innate immunity in the central nervous system leads to primary astrocyte dysfunction followed by demyelination[J]. Acta Neuropathologica,2010, 120(2): 223-236.
[12] CHRONAIOU I, STENSJØEN A L, SJØBAKK T E, et al. Impacts of MR spectroscopic imaging on glioma patient management[J]. Acta Oncologica(Stockholm, Sweden),2014, 53(5): 580-589.
[13] BOLCAEN J, ACOU M, MERTENS K, et al. Structural and metabolic features of two different variants of multiple sclerosis: a PET/MRI study[J]. Journal of Neuroimaging: Official Journal of the American Society of Neuroimaging,2013, 23(3): 431-436.
[14] CHA S, PIERCE S, KNOPP E A, et al. Dynamic contrast-enhanced T2*-weighted MR imaging of tumefactive demye-linating lesions[J]. AJNR American Journal of Neuroradiolo-gy,2001, 22(6): 1109-1116.
[15] JAIN R, ELLIKA S, LEHMAN N L, et al. Can permeability measurements add to blood volume measurements in differentiating tumefactive demyelinating lesions from high grade gliomas using perfusion CT?[J]. Journal of Neuro-oncology,2010, 97(3): 383-388.

备注/Memo

备注/Memo:
基金项目:福建省自然科学基金资助项目(2021J011409)
通信作者:陈玉珊,Email:cys6899@163.com
更新日期/Last Update: 2024-11-20